Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,380 result(s) found. Displaying page 1,162 of 2,219.
    EudraCT Number: 2006-003323-37 Sponsor Protocol Number: MCI-196-E07 Start Date*: 2007-01-29
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Randomised, Double-blind, Multi-centre, Withdrawal Study comparing MCI-196 versus Placebo in Chronic Kidney Disease Stage V Subjects on Dialysis with Hyperphosphataemia (Incorpora...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) CZ (Completed) FR (Completed) DE (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002473-47 Sponsor Protocol Number: NV20235 Start Date*: 2007-01-25
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients
    Medical condition: Seasonal prophylaxis of influenza in immonucompromised subjects
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Influenza LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LT (Completed) FR (Completed) CZ (Completed) BE (Completed) EE (Completed) IT (Completed) PL (Ongoing) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002749-35 Sponsor Protocol Number: 0881A3-404 Start Date*: 2007-04-13
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: A Multicentre, Double-Blind, Placebo-Controlled, Randomized Study of Etanercept in the Treatment of Adults Patients with Refractory Heel Enthesitis in Spondylarthropathy
    Medical condition: Refractory heel enthesitis in spondylarthropathy.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10058497 Enthesitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002425-31 Sponsor Protocol Number: 05-SMOF-006 Start Date*: 2007-03-19
    Sponsor Name:Fresenius Kabi Deutschland GmbH
    Full Title: A double-blind, randomised study comparing the safety and tolerance of SMOFlipid 20% and Intralipid 20% in long-term treatment with parenteral nutrition
    Medical condition: Supply of energy, essential fatty acids and omega-3 fatty acids to adults, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10051284 Parenteral nutrition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-001975-12 Sponsor Protocol Number: V00191 PO 202 Start Date*: 2007-07-18
    Sponsor Name:PIERRE FABRE MEDICAMENT - IDPF
    Full Title: Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel...
    Medical condition: Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) FI (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003560-62 Sponsor Protocol Number: R092670PSY3006 Start Date*: 2007-03-28
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Double-Blind, Parallel-Group, Comparative Study of Flexible Doses of Paliperidone Palmitate and Flexible Doses of Risperidone Long-Acting Intramuscular Injection in Subjects with Schi...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) LT (Completed) DE (Completed) AT (Completed) FR (Completed) CZ (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005212-27 Sponsor Protocol Number: D9614C00096 Start Date*: 2007-05-03
    Sponsor Name:AstraZeneca AB
    Full Title: A phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Treatment-withdrawal Study to Evaluate the Efficacy and Safety of Esomeprazole for the Treatment of Gastroeso...
    Medical condition: This Phase III study will evaluate esomeprazole for reducing the esophageal and supraesophageal signs and symptoms of infantile gastro-esophageal reflux disease (GERD) in infants aged 1 to 11 month...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017885 Gastrooesophageal reflux disease LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-004553-17 Sponsor Protocol Number: CC-4047-MMM-001 Start Date*: 2007-04-24
    Sponsor Name:Celgene Corporation
    Full Title: A PHASE 2, PROSPECTIVE, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, ACTIVE- CONTROL, PARALLEL-GROUP STUDY TO DETERMINE THE SAFETY OF AND TO SELECT A TREATMENT REGIMEN OF CC-4047 EITHER AS SINGLE-AGENT O...
    Medical condition: Myelofibrosis with myeloid metaplasia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028538 Myelofibrosis with myelometaplasia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Completed) AT (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-005270-47 Sponsor Protocol Number: 309363 Start Date*: 2007-04-23
    Sponsor Name:Schering AG
    Full Title: International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with (Phase A) double-blind Betaseron/Betaferon 250 µg or 500 µg...
    Medical condition: relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028245 Multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed) IE (Completed) FR (Completed) AT (Completed) SE (Completed) ES (Completed) DE (Completed) HU (Completed) LV (Completed) SI (Completed) NL (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002257-76 Sponsor Protocol Number: 3074K5-319-WW Start Date*: 2006-12-20
    Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Comparison Study of the Safety and Efficacy of a Once-Daily Dose of Tigecycline versus Ertapenem for the Treatment of Foot Infections in Subjects with Diabetes
    Medical condition: Subjects with diabetes with a qualifying foot infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060803 Diabetic foot infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) SE (Prematurely Ended) LT (Completed) SK (Completed) FI (Completed) GB (Completed) LV (Completed) PT (Completed) EE (Completed) FR (Completed) AT (Completed) GR (Completed) DE (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-006344-59 Sponsor Protocol Number: N01252 Start Date*: 2007-06-07
    Sponsor Name:UCB Pharma S.A.
    Full Title: A multi-center, double-blind, parallel-group, placebo-controlled, randomized study: evaluation of the efficacy and safety of brivaracetam in subjects (>= 16 to 70 years old) with Partial Onset Seiz...
    Medical condition: Partial Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015037 Epilepsy LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) FR (Completed) GB (Completed) HU (Completed) FI (Completed) IT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-003324-11 Sponsor Protocol Number: MCI-196-E09 Start Date*: 2007-03-28
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation
    Full Title: A Phase III, Double-blind, Multi-centre, Randomised, Parallel Group Design, Placebo-controlled, Flexible Dose Study of MCI-196 in Combination with a Calcium-based Phosphate Binder in Chronic Kidney...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) AT (Completed) GB (Completed) FR (Completed) ES (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002907-15 Sponsor Protocol Number: AC-051-350 Start Date*: 2007-03-21
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Multicenter, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of tezosentan in patients with pre-operative pulmonary hypertension, ...
    Medical condition: Cardiac Surgery, Separation from cardiopulmonary bypass
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063082 Acute right ventricular failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) FR (Completed) AT (Completed) SK (Completed) IT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006309-96 Sponsor Protocol Number: 0881A6-3326 Start Date*: 2007-06-08
    Sponsor Name:Wyeth Pharmaceuticals France
    Full Title: A 3 Month, Randomised, Open Label, Parallel Group, Descriptive Study to Explore and Compare Perceptions and Satisfaction for Two Different Delivery Mechanisms for Etanercept (Etanercept Autoinjecto...
    Medical condition: PSORIASIS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) BE (Completed) FI (Completed) ES (Completed) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-002584-70 Sponsor Protocol Number: 155-CL-009 Start Date*: 2007-09-14
    Sponsor Name:Astellas Pharma US, Inc.
    Full Title: A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
    Medical condition: Diffuse large B-cell Lymphoma refractory
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012822 Diffuse large B-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-006878-22 Sponsor Protocol Number: R00002 CR 201 (ORF) Start Date*: 2007-12-11
    Sponsor Name:Orfagen
    Full Title: Efficacy and tolerance of Tazarotene cream in lamellar ichthyosis (LI): a dose-finding study.
    Medical condition: Lamellar Ichthyosis (LI)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003158-12 Sponsor Protocol Number: H3E-MC-JMHR Start Date*: 2007-01-11
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Randomized Phase 3 Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
    Medical condition: Recurrent or Metastatic Head and Neck Cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060121 Squamous cell carcinoma of head and neck LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) HU (Completed) DE (Completed) DK (Completed) IT (Completed) BE (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-002875-42 Sponsor Protocol Number: 1199.30 Start Date*: 2007-07-06
    Sponsor Name:Boehringer Ingelheim
    Full Title: A 12 month, double blind, randomized, placebo-controlled trial evaluating the effect of BIBF 1120 administered at oral doses of 50 mg qd, 50 mg bid, 100 mg bid and 150 mg bid on Forced Vital Capaci...
    Medical condition: Idiopathic pulmonary fibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021240 Idiopathic pulmonary fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NL (Completed) IE (Completed) ES (Completed) HU (Completed) CZ (Completed) FR (Completed) IT (Completed) PT (Completed) GR (Completed) BG (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001262-87 Sponsor Protocol Number: Fx-006 Start Date*: 2008-07-04
    Sponsor Name:FoldRx Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension of Study Fx-005 Evaluating Long-Term Safety and Clinical Outcomes of Fx-1006A in Patients with Transthyretin Amyloid Polyneuropathy
    Medical condition: Transthyretin Amyloid Polyneuropathy (ATTR-PN)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057949 Familial amyloid polyneuropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-002920-14 Sponsor Protocol Number: VX-950-TiDP24-C209 Start Date*: 2007-11-14
    Sponsor Name:Tibotec BVBA
    Full Title: A Phase IIa randomized, partially blinded trial of telaprevir (VX-950) in treatment-naïve subjects with chronic genotype 2 or 3 hepatitis C infection
    Medical condition: Hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008912 Chronic hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Feb 11 00:11:26 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA